September 2016

Sekisui XenoTech Joins Fight Against Liver Disease

Author: Dr. Maciej Czerwinski, Michael Millhollen Posted: 16 September 2016

Currently, there are no approved therapies for NASH, yet nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects 1-in-4 people worldwide. Research BioBank provides disease-defined liver tissue samples and hepatocytes as a convenient human model for hepatic disease research...

Read more